Denmark-based ExpreS2ion Biotechnologies has executed a non-exclusive research license agreement with Boston Children’s Hospital (Boston Children’s) to use its recombinant protein expression platform ExpreS2 for the hospital’s academic research.
Boston Children’s is the paediatric teaching affiliate of Harvard Medical School.
The ExpreS2 platform is being used to solve protein expression challenges and has proven to be instrumental in advancing research in neglected diseases, including malaria research and vaccine projects.
The system offers high quality, homogenous expressed proteins, qualities that are needed in structural biology studies.
ExpreS2 is instrumental in advancing research for these neglected diseases where other expression systems failed to yield native properties of the parasite proteins or even failed to express the proteins.
ExpreS2ion chief scientific officer Wian de Jongh said: "ExpreS2ion aims to support the development of novel drugs through solving protein production challenges.
"Our proprietary technology platform can deliver protein for laboratory use and is also compatible with current good manufacturing practices (cGMP).
"This interaction with Boston Children’s is part of our strategy to support top academic teams in protein expression. It is our hope that this license will advance the understanding of relevant immunological processes and of malaria vaccine candidates."
Last month, Boston Children’s selected VitalHealth Software’s QuestLink for the implementation of the International Consortium for Health Outcomes Measurement (ICHOM) standard set for cleft lip and palate.
ICHOM certified QuestLink to support the efficient gathering of patient reported outcomes (PROs) included in its standard sets.
Starting this month, the hospital will implement QuestLink, making it the first children’s hospital in the US to collect ICHOM standard sets electronically.